PGPeilin Guo

Peilin Guo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Peilin Guo has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Guanghui Ma

    State Key Laboratory of Biochemical Engineering Institute of Process Engineering Chinese Academy of Sciences Beijing 100190 P. R. China

    1 shared publication
  • Hua Yue

    State Key Laboratory of Biochemical Engineering Institute of Process Engineering Chinese Academy of Sciences Beijing 100190 P. R. China

    1 shared publication
  • Shuang Wang

    State Key Laboratory of Biochemical Engineering Institute of Process Engineering Chinese Academy of Sciences Beijing 100190 P. R. China

    1 shared publication
  • Wei Wei

    State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, People’s Republic of China

    1 shared publication
  • Xiao Zhang

    State Key Laboratory of Biochemical Engineering Institute of Process Engineering Chinese Academy of Sciences Beijing 100190 P. R. China

    1 shared publication
  • Xin Li

    Department of Gastroenterology, Shandong Provincial Lab for Clinical Immunology Translational Medicine in Universities, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital

    1 shared publication

Latest Publications

  • Advancement of Engineered Bacteria for Orally Delivered Therapeutics

    by Peilin Guo, Shuang Wang, Hua Yue, Xiao Zhang, Guanghui Ma, Xin Li, Wei Wei

    The use of bacteria and their biotic components as therapeutics has shown great potential in the treatment of diseases. Orally delivered bacteria improve patient compliance compared with injection‐administered bacteria and are considered the preferred mode. However, due to the harsh gastrointestinal environment, the viability and therapeutic efficacy of orally delivered bacteria are significantly reduced in vivo. In recent years, with the rapid development of synthetic biology and nanotechnology, bacteria and biotic components have been engineered to achieve directed genetic reprogramming for construction and precise spatiotemporal control in the gastrointestinal tract, which can improve viability and therapeutic efficiency. Herein, a state‐of‐the‐art review on the current progress of engineered bacterial systems for oral delivery is provided. The different types of bacterial and biotic components for oral administration are first summarized. The engineering strategies of these bacteria and biotic components and their treatment of diseases are next systematically summarized. Finally, the current challenges and prospects of these bacterial therapeutics are highlighted that will contribute to the development of next‐generation orally delivered bacteriotherapy.